Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives “Neutral” Rating from Wedbush

Ultragenyx Pharmaceutical (NASDAQ:RARE)‘s stock had its “neutral” rating reissued by equities research analysts at Wedbush in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $25.00 target price on the biopharmaceutical company’s stock. Wedbush’s price target indicates a potential upside of 21.49% from the company’s current price.

Other analysts also recently issued reports about the company. Robert W. Baird dropped their price objective on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Barclays reduced their price objective on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, November 24th. Wells Fargo & Company reduced their price target on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 30th. TD Cowen reduced their price target on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Finally, Jefferies Financial Group dropped their price objective on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research note on Tuesday, December 30th. Sixteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $71.18.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $20.58 on Tuesday. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $45.00. The company has a market capitalization of $1.99 billion, a PE ratio of -3.48 and a beta of 0.16. The stock has a fifty day moving average of $26.59 and a two-hundred day moving average of $29.72.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The business had revenue of $207.00 million for the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 566.58% and a negative net margin of 85.54%.Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same quarter last year, the business earned ($1.39) EPS. As a group, equities research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,081 shares of the firm’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $36.38, for a total transaction of $112,086.78. Following the completion of the transaction, the chief financial officer directly owned 95,146 shares of the company’s stock, valued at $3,461,411.48. This trade represents a 3.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 6,227 shares of company stock worth $187,126. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after buying an additional 29,984 shares during the last quarter. CWM LLC boosted its holdings in Ultragenyx Pharmaceutical by 1,171.2% in the second quarter. CWM LLC now owns 4,144 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 3,818 shares during the period. Nordea Investment Management AB raised its holdings in shares of Ultragenyx Pharmaceutical by 59.8% during the second quarter. Nordea Investment Management AB now owns 60,176 shares of the biopharmaceutical company’s stock worth $2,208,000 after purchasing an additional 22,509 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $715,000. Finally, Privium Fund Management B.V. grew its position in shares of Ultragenyx Pharmaceutical by 1.4% during the 2nd quarter. Privium Fund Management B.V. now owns 253,304 shares of the biopharmaceutical company’s stock valued at $9,185,000 after buying an additional 3,500 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.